Guardant Health Posts 44% Revenue Jump, Raises 2026 Guidance on Shield Momentum
Precision oncology company lifts full-year revenue outlook to $1.34-$1.36 billion as colorectal cancer screening test gains commercial traction.
Strong Quarter Across Portfolio
Guardant Health reported second quarter 2026 revenue of $335.0 million, representing 44% growth compared to the same period in 2025, according to an 8-K filing with the Securities and Exchange Commission (8-K filing, 2026-07-30). The Palo Alto-based precision oncology company raised its full-year 2026 revenue guidance to a range of $1.34 to $1.36 billion, reflecting growth of 36% to 38%, up from prior guidance of $1.30 to $1.32 billion.
The company's oncology division generated $219.1 million in revenue, a 38% increase, while processing approximately 104,000 oncology tests, representing 63% volume growth year-over-year (8-K filing, 2026-07-30). Screening revenue, driven by the Shield colorectal cancer blood test, surged over 250% to $52.9 million from $14.8 million in the prior year period, with test volume reaching approximately 66,000 compared to 16,000 tests a year earlier.
Regulatory and Commercial Milestones
The quarter included several significant developments for Guardant's product portfolio. The company received FDA approval for Guardant360 Liquid CDx, described as "the most advanced FDA-approved liquid biopsy panel" (8-K filing, 2026-07-30). The Shield blood test achieved inclusion in the American Cancer Society's updated colorectal cancer screening guidelines and obtained coverage from UnitedHealth Group, marking the first major commercial insurer to provide coverage for the test.
"The inclusion of the Shield blood test in the American Cancer Society's screening guidelines, together with UnitedHealth Group's broad coverage decision, represents powerful validation of Shield's clinical utility and its potential to improve access to screening," said AmirAli Talasaz, co-founder and co-CEO (8-K filing, 2026-07-30).
Financial Performance and Margins
Non-GAAP gross margin improved to 67% for the second quarter of 2026, compared to 66% in the prior year period (8-K filing, 2026-07-30). However, operating expenses increased to $348.1 million from $257.3 million year-over-year, primarily due to commercial infrastructure expansion and marketing activities supporting Shield and oncology growth.
The company reported a GAAP net loss of $120.1 million, or $0.90 per share, compared to a net loss of $99.9 million, or $0.80 per share, in the second quarter of 2025 (8-K filing, 2026-07-30). Non-GAAP net loss was $56.2 million, or $0.42 per share, compared to $55.0 million, or $0.44 per share, in the prior year period. Free cash flow was negative $69.5 million for the quarter.
Guardant held $1.2 billion in cash, cash equivalents, and restricted cash as of June 30, 2026 (8-K filing, 2026-07-30).
Updated Full-Year Outlook
For full-year 2026, the company now expects oncology revenue to grow approximately 30%, up from prior guidance of 28% to 29%, with oncology volume expected to grow approximately 50% versus earlier guidance of approximately 35% (8-K filing, 2026-07-30). Screening revenue guidance increased to $218 to $230 million, driven by Shield volume of 270,000 to 285,000 tests, compared to prior guidance of $186 to $198 million in revenue and 230,000 to 245,000 tests.
The company raised its full-year non-GAAP operating expense guidance to $1.08 to $1.10 billion from $1.05 to $1.07 billion, and now expects free cash flow burn of $195 million to $205 million, representing improvement from $233 million burned in full-year 2025 (8-K filing, 2026-07-30).
According to MarginX data, Guardant is scheduled to present at Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026, and at Morgan Stanley's 24th Annual Global Healthcare Conference on September 15, 2026.
This article was generated by MarginX from the 8-K filing on 2026-07-30. It is not investment advice.